FibroGen
Michael Barnes is a seasoned professional with extensive experience in both scientific research and public service. Currently a Senior Scientist at FibroGen, Inc. since June 2019, Michael has previously held roles as a Research Scientist at the same company and has significant analytical chemistry experience from Theravance. Michael's background also includes over eight years in local government as Councilman and Mayor for the City of Brisbane, demonstrating a strong commitment to community leadership. Earlier career roles include positions in protein expression and preclinical research at Khepri/Arris/Axys and supervisory responsibilities in manufacturing at Genentech. Michael holds an educational background from the University of California, Berkeley.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.